Remove Immune Response Remove In-Vitro Remove Life Science Remove Protein
article thumbnail

Lab to jab in 100 days: manufacturing flexibility for future rapid responses

Pharmaceutical Technology

The mission was first put forward during the UK’s G7 Presidency of June 2021, with support from representatives of the life sciences industry. billion towards the “pandemic-busting plan”, which involves the investigation of rapid response vaccine technologies. Single- and multi-nation funding opportunities flooded in.

article thumbnail

COVID-19 Vaccine Messaging: Why Vaccine Efficacies Can’t Be Compared and Shopped

XTalks

In light of this, vaccine makers and regulatory bodies will need to share vaccine data and science in a clear and rigorous manner in order to clearly communicate why there is no one best vaccine, and why each authorized vaccine is a superlative tool in battling COVID-19.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How T Cell Tests Could Trump Antibody Tests in the Detection of COVID-19

XTalks

The cell-based tests are designed to identify specific T cells that are activated in response to a pathogen — which in this case would be SARS-CoV-2. Traditional antibody tests for uncovering past infections involve detection of antigen-specific antibodies produced during an immune response against a pathogen.

article thumbnail

COVID-19 Pandemic Coverage

XTalks

The company’s candidate vaccine, mRNA-1273, is a synthetic messenger RNA that encodes the stabilized SARS-CoV-2 spike protein. The University of Oxford/AstraZeneca partnership, in turn, is testing a viral-vectored coronavirus vaccine that again expresses the spike protein of SARS-CoV-2 virus. The price of that prize is incalculable.